Log In
BCIQ
Print this Print this
 

ATL1103, COR-004

  Manage Alerts
Collapse Summary General Information
Company Antisense Therapeutics Ltd.
DescriptionSecond-generation antisense inhibitor of growth hormone receptor expression
Molecular Target Growth hormone receptor
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentPhase II
Standard IndicationAcromegaly
Indication DetailsTreat acromegaly
Regulatory Designation
PartnerIonis Pharmaceuticals Inc.;
Strongbridge Biopharma plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$110.0M

$3.0M

$105.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/14/2015

$110.0M

$3.0M

$105.0M

Get a free BioCentury trial today